Catalog No.
Product Name
Application
Product Information
Citations
-
PTPN2 Degrader
PROTAC PTPN2 degrader-1 is an effective degrader of the protein tyrosine phosphatase PTPN2. This compound facilitates target protein degradation through the proteasome pathway, enabling the modulation of cellular signaling related to cancer and metabolic diseases. Its application in research may provide insights into the therapeutic potential of targeting PTPN2 in various disease contexts. -
CDK2 molecular glue Degrader
CDK2 degrader 1 is a selective molecular glue degrader targeting cyclin-dependent kinase 2 (CDK2). It effectively induces ubiquitination and proteasomal degradation of CDK2 by binding to cereblon, achieving a Dmax greater than 80% and a Ki greater than 1 μM. This compound is utilized in cancer research, providing insights into tumor biology and potential therapeutic strategies. -
PROTAC EED Degrader
PROTAC EED degrader-1 is a von Hippel-Lindau-based PROTAC that selectively targets EED with a pKD of 9.02. This compound functions as a polycomb repressive complex 2 (PRC2) inhibitor, exhibiting an inhibitory potency characterized by a pIC50 of 8.17. It serves as a valuable tool for researching the modulation of PRC2 activity and its implications in cancer biology and epigenetic regulation. -
IKZF2/CK1α Molecular Gel
DEG-77 is a molecular glue that targets IKZF2 and CK1α, demonstrating DC50 values of 15.3 nM and 10 nM, respectively. This compound exerts notable anti-tumor effects by enhancing the transcription of the pro-apoptotic protein Bax and promoting the expression of the cell cycle regulator p21. DEG-77 is relevant for research in acute myeloid leukemia (AML), diffuse large B-cell lymphoma, and ovarian cancer. -
RIPK1 PROTAC Degrader
LD4172 is a selective RIPK1 PROTAC degrader that exhibits a Ki of 4.8 nM. It facilitates RIPK1 protein degradation through the formation of a ternary complex with RIPK1 and VHL E3 ligase, leading to ubiquitination and proteasomal degradation. LD4172 effectively inhibits TNF-induced classical NF-κB signaling in TRAF2-deficient cells, significantly reducing IκBα phosphorylation and IL-8 production. Additionally, it promotes apoptosis and immunogenic cell death in tumor cells, enhances tumor-infiltrating lymphocyte responses, and sensitizes tumors to anti-PD1 therapy, making it a valuable chemical probe for studying RIPK1-related functions in melanoma and colon cancer research. -
CDK2/4/6 PROTAC Degrader
PROTAC CDK2/4/6 Degrader-2 is a targeted protein degradator specifically designed to degrade cyclin-dependent kinases CDK2, CDK4, and CDK6. This compound effectively inhibits cell proliferation and induces cell cycle arrest and apoptosis in malignant melanoma cells. Its application extends to cancer research, particularly in investigating the role of CDK2/4/6 in tumor biology. The compound can also be converted into its prodrug form, enabling versatile utilization in various assays related to cancer therapeutics. -
Molecular Glue Degrader
BTX306 is a cereblon-targeting molecular glue degrader that effectively reduces myeloma cell viability and induces apoptosis. This compound demonstrates the ability to overcome resistance in myeloma cells to traditional therapies such as Lenalidomide and Bortezomib. Additionally, BTX306 displays potent activity against primary myeloma cells and exhibits substantial efficacy in in vivo models. This reagent is suitable for research focusing on myeloma and related therapeutic strategies. -
BRD4 Degrader
PROTAC BRD4 Degrader-6 is a potent small-molecule degrader that targets BRD4, exhibiting an IC50 value of 2.7 nM for the BRD4 BD1 domain. This compound effectively degrades BRD4 protein and leads to the downregulation of c-Myc expression. In vitro studies demonstrate its capacity to inhibit proliferation and induce apoptosis in the pancreatic cancer cell line BxPC3, making it a valuable tool for research in human pancreatic cancer biology. -
PROTAC Ferritin Degrader
DeFer-2 is a PROTAC degrader targeting ferritin, with a Kd of 17.1 μM. By inducing ferritin degradation, DeFer-2 leads to caspase 3-GSDME-mediated pyroptosis in cancer cells, driven by an accumulation of free iron and elevated reactive oxygen species (ROS). This compound demonstrates significant tumor growth inhibition and extends survival in mouse models bearing B16F10 subcutaneous tumors, making it a valuable tool for research in melanoma. -
AURKA PROTAC Degrader
SK2188 is a potent and selective PROTAC degrader that targets Aurora Kinase A (AURKA) with a DC50 of 3.9 nM. It induces DNA damage and promotes apoptosis in cancer cells, effectively leading to the degradation of MYCN. SK2188 serves as a valuable tool for investigating tumor cell proliferation and exploring therapeutic strategies in MYCN-amplified neuroblastoma. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG1-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker, designed for applications in PROTAC (proteolysis-targeting chimeras) technology. This reagent facilitates the targeted degradation of specified proteins, providing a valuable tool for researchers studying protein homeostasis and therapeutic intervention. Its unique properties make it suitable for various applications in chemical biology, drug discovery, and targeted protein degradation studies. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted protein degradation. Its application is critical in studying the modulation of protein levels in various biological contexts, providing valuable insights into cellular pathways and disease mechanisms. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate the cereblon ligand derived from Thalidomide, along with a flexible linker suitable for PROTAC technology. This compound facilitates targeted protein degradation by linking specific binders to E3 ligases, enabling the modulation of protein expression in cellular studies. Its applications extend to research in drug discovery and the development of innovative therapeutic strategies involving targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates E3
Thalidomide-O-C6-azide is an E3 ligase ligand-linker conjugate that combines the Thalidomide-based cereblon ligand with a versatile linker utilized in PROTAC technology. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. Thalidomide-O-C6-azide is valuable for applications in targeted protein degradation and chemical biology studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH-Boc is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for use in PROTAC (proteolysis-targeting chimera) applications. This compound serves as a crucial building block for synthesizing MI-389, a potent phthalimide-based degrader derived from the multi-targeted receptor tyrosine kinase inhibitor sunitinib. Thalidomide-NH-C6-NH-Boc enables targeted protein degradation, facilitating research into protein regulation and therapeutic discovery in oncology and other fields. -
SMARCA2 Degrader
A947 is a selective SMARCA2 proteolysis-targeting chimera (PROTAC) that functions as a potent degrader of SMARCA2. It exhibits a binding affinity to the SMARCA2 bromodomain with a Kd value of 93 nM, establishing its effectiveness in mediating targeted protein degradation. This compound has significant applications in cancer research, facilitating studies on the role of SMARCA2 in tumorigenesis and potential therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride functions as an E3 ligase ligand-linker conjugate with high affinity for cereblon (CRBN). This compound is pivotal in the development of Proteolysis Targeting Chimeras (PROTACs), offering a strategic approach to induce targeted protein degradation. Its utility extends to research applications in cellular signaling pathways and therapeutic target validation, enabling the exploration of novel treatment modalities in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG1-NH2 is an E3 ligase ligand-linker conjugate that leverages the Thalidomide-derived cereblon ligand, facilitating targeted protein degradation through the PROTAC technology framework. This compound is designed for use in research applications aimed at elucidating E3 ligase biology and developing innovative therapeutic strategies. Its unique structure promotes effective interactions with cellular proteins, enhancing the specificity and efficiency of targeted degradation approaches. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a hexylamine linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It demonstrates significant potential in biochemical research, particularly in drug discovery and development focused on modulating protein levels through E3 ligase recruitment. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG2-C2-NH-Boc is an E3 ligase ligand-linker conjugate that features a thalidomide-based cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound is designed for the synthesis of dBRD9, a selective PROTAC degrader that targets BRD9, facilitating investigations into BAF complex biology. It serves as a valuable tool in research applications focused on targeted protein degradation and the modulation of cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. Its unique structure allows for the recruitment of E3 ligases, making it valuable in studies related to cellular processes and therapeutic development for various diseases. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-PEG2-C2-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in the PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation by promoting interactions with E3 ligases. It is applicable in research focused on cellular protein regulation and therapeutic development in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C3-PEG3-C1-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a three-unit PEG linker. This compound facilitates targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology, enhancing the specificity and efficacy of the therapeutic approach. It is suitable for research applications in the areas of protein modulation and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride is a conjugate that targets E3 ligases, featuring a specific ligand and a flexible linker. This compound exhibits immunomodulatory properties and is utilized in cancer research, aiding investigations into targeted protein degradation and therapeutic strategies. Its unique structure facilitates the study of E3 ligase interactions, making it a valuable tool in oncology and drug development research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG2 linker, facilitating targeted protein degradation through the PROTAC technology. This compound is designed to enhance the specificity and efficacy of protein recruitment to the E3 ligase, making it a valuable tool for investigating the mechanisms of targeted ubiquitination and therapeutic intervention in various diseases. Its applications extend to drug discovery, particularly in the development of innovative treatments for conditions reliant on protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is an engineered E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand combined with a three-unit PEG linker suitable for PROTAC technology. This compound facilitates targeted protein degradation through selective E3 ligase recruitment, making it valuable for studies in cellular biology and therapeutic applications. Its unique structure enhances solubility and stability in biological systems, promoting efficient conjugation in research endeavors. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-COOH is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand combined with a PEG3 linker. This compound facilitates the targeted ubiquitination of specific proteins through PROTAC technology, promoting their degradation. It serves as a valuable tool for studies involving protein regulation and the development of targeted protein degradation strategies in cellular and molecular biology research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG1-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand, designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound is a versatile click chemistry reagent, possessing an alkyne moiety that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique structure enables targeted protein degradation, making it a valuable tool for research in cellular signaling and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand combined with a PEG3 linker, designed for use in PROTAC technology. This compound functions as a click chemistry reagent, possessing an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its applications in targeted protein degradation research make it a valuable tool for exploring protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG3-COOH is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a PEG3 linker. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation. Its mechanism allows for selective modulation of protein levels, making it valuable in drug discovery and therapeutic research focused on protein homeostasis and regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride serves as a synthesized E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a three-unit polyethylene glycol (PEG) linker. This compound is essential for the development of proteolysis-targeting chimeras (PROTACs), enabling targeted degradation of specific proteins in cellular research. Its unique structure facilitates effective interactions with E3 ligases, making it a valuable tool for studying protein regulation and potential therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand connected by a PEG3 linker. This compound is designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. Its biological activity makes it suitable for applications in protein regulation studies and drug discovery research, particularly in exploring E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate designed to engage cereblon, a key target in the ubiquitin-proteasome system. This compound serves as a crucial component in PROTAC technology, facilitating targeted protein degradation. Its utility in research includes the development of novel therapeutic strategies aimed at modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon. This compound utilizes a Thalidomide-based ligand and incorporates a PEG2 linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) technology. It is primarily used in chemical biology research to modulate protein levels through targeted degradation, making it valuable for investigations in cancer and other diseases where protein regulation is essential. -
PROTAC Linkers
Thalidomide-O-amido-PEG4-propargyl is a PEG-based PROTAC linker designed for the synthesis of Proteolysis Targeting Chimeras (PROTACs). This compound features an alkyne functional group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) for efficient conjugation with azide-containing molecules. Its unique properties enable precise modulation of target protein degradation, supporting research in targeted protein modulation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C8-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from thalidomide, combined with a C8 linker. This compound is designed for use in PROTAC technology, facilitating the targeted degradation of proteins via the ubiquitin-proteasome pathway. Its application in chemical biology includes studies of protein modulation and therapeutic strategies in oncology and other disease models, enabling researchers to explore novel approaches in targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the Thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enhancing cellular activity against specific protein targets. Its unique structure supports applications in drug development and research focused on modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that integrates the Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted degradation of specific proteins via the ubiquitin-proteasome pathway, making it a valuable tool for research in targeted protein modulation. Its application extends to studies in cancer biology and therapeutic development, where selective protein degradation is crucial. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-NH-Boc is an E3 Ligase Ligand-Linker Conjugate that targets Cereblon. This compound facilitates the recruitment of the CRBN protein, playing a critical role in the development of targeted protein degradation strategies. The Boc protecting group can be easily removed under acidic conditions, enabling its use in the synthesis of PROTAC molecules. Thalidomide-NH-PEG3-NH-Boc serves as a key intermediate for CRBN-based PROTAC applications in chemical biology research. -
E3 Ligase Ligand
Thalidomide-5-methyl functions as an E3 ligase ligand, specifically targeting cereblon (CRBN). This compound facilitates the recruitment of CRBN protein, enabling the development of PROTAC (proteolysis-targeting chimeras) for targeted protein degradation strategies. Thalidomide-5-methyl is a valuable tool in chemical biology and drug discovery research, particularly for studies related to targeted therapies and the modulation of protein stability. -
E3 Ligase Ligand-Linker Conjugates Chemical
Thalidomide-4-O-C10-COOH is an E3 ligase ligand-linker conjugate utilized in the synthesis of PROTAC (proteolysis-targeting chimera) compounds. This reagent facilitates targeted protein degradation by promoting the ubiquitination of specific substrates via E3 ligase interaction. It is particularly valuable in drug discovery and development, offering a novel approach for modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound combines the Thalidomide-derived ligand, which targets cereblon, with a PEG4 linker to facilitate the development of bifunctional degraders. Its primary application lies in the degradation of target proteins, enabling novel therapeutic strategies in cancer and other diseases by harnessing the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C6-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand within its structure. This compound serves as a crucial building block in the design and synthesis of PROTACs (proteolysis targeting chimeras). Its unique properties facilitate targeted protein degradation, enabling significant advancements in therapeutic research and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand paired with a C8 linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimera) applications, facilitating targeted protein degradation through the induction of ubiquitin-proteasome pathway involvement. Its unique structure allows for efficient cellular uptake and modulation of specific protein levels, making it invaluable for research in cellular signaling, disease modeling, and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine hydrochloride is an E3 ligase ligand-linker conjugate, combining a thalidomide derivative that targets cereblon with a PEG4 linker. This compound is designed for use in Proteolysis Targeting Chimera (PROTAC) technology, facilitating the targeted degradation of specific proteins. Its application extends to various studies in cellular signaling and protein homeostasis, making it a valuable reagent for drug discovery and development in the field of targeted therapies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C4-COOH is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a synthetic linker for targeted protein degradation applications. This compound is designed to facilitate the selective degradation of target proteins through the PROTAC (proteolysis-targeting chimera) mechanism. Its utility spans various biochemical research applications, especially in studies investigating the modulation of intracellular protein levels and the development of therapeutic strategies targeting specific cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a component of the CRL4 E3 ligase complex. This compound serves as a key element in PROTAC (proteolysis-targeting chimera) technology, facilitating targeted protein degradation. Its biological activity supports research in protein regulation, cellular signaling, and therapeutic strategies for disease intervention. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C6-NHBoc is an E3 ligase ligand-linker conjugate that combines the Thalidomide derivative with a hexyl linker suitable for use in PROTAC technology. This compound functions primarily by targeting cereblon, facilitating the degradation of specific proteins through induced ubiquitination. It is valuable for research applications involving targeted protein degradation and the modulation of signaling pathways associated with various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-Propargyl is an E3 ligase ligand-linker conjugate that features the cereblon ligand derived from Thalidomide, along with a PEG4 linker designed for PROTAC technology. This compound serves as a versatile click chemistry reagent due to its alkyne functionality, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique properties facilitate targeted protein degradation and make it valuable for research applications in drug discovery and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through the PROTAC technology, promoting the recruitment of E3 ligases to specific substrates. Its key biological activity makes it a valuable tool for research in cellular regulation, protein homeostasis, and potential therapeutic applications in various diseases.
